Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
Background Immune checkpoint inhibitors (ICIs) have been increasingly used in patients with various cancers and have shown efficient therapeutic outcomes. However, fewer than 40% of cases across multiple cancer types show a response to ICIs. Therefore, developing more efficient combinational approac...
Salvato in:
| Autori principali: | , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2022-05-01
|
| Serie: | Journal for ImmunoTherapy of Cancer |
| Accesso online: | https://jitc.bmj.com/content/10/5/e003819.full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|